

**07:30** Registration & Coffee

**08:20** Welcome Speech by Leonard Sachs, Managing Director, Sachs Associates

**08:30** Keynote Speech: "Neuroscience in a Time of Uncertainty" by Harry Tracy, President, NI Research, Inc.

**08:50**

### Neurotherapeutics-in-Development: The Next Five Years

Chaired by:

Harry Tracy, President, NI Research, Inc.

Panelists:

Darryle Schoepp, VP, Neuroscience, Merck & Co., Inc.

David Bleakman, VP, CSO - Neuroscience Discovery Research, New York City, Eli Lilly and Co.

Kees Been, Founder, President and CEO, Lysosomal Therapeutics, Inc.

Todd Sherer, CEO, The Michael J. Fox Foundation

**09:30**

### Bio Partnering & DealMaking Panel

Co-Chaired by:

Bruce Leuchter, Managing Director, PJT Partners

Kiran Reddy, Venture Partner, Clarus Ventures, LLC

Panelists:

Carlos Buesa, CEO, Oryzon Genomics SA

Derek Small, President & CEO, Assembly Biosciences

Isaac Veinbergs, Head of External Innovation, Neurosciences, Sanofi

Martin Heidecker, Managing Director, Boehringer Ingelheim Venture Fund USA, Inc.

Noelle Dubiansky, Partner, Goodwin Procter LLP

Shafique Virani, Head of Neuroscience, Ophthalmology and Rare Diseases Partnering, F. Hoffmann La Roche Ltd.

**10:10** Coffee Break

**10:25**

### Advances in Alzheimer's Disease Panel

Chaired by:

Ryan Westphal, Sr. Director, Neuroscience Search & Evaluation, Eli Lilly and Co.

Panelists:

Eugene Williams, Executive Chairman, ProMIS™ Neurosciences, Inc.

Hendrik Liebers, CFO, Probiodrug AG

Howard Fillit, Founding Executive Director and CSO, The Alzheimer's Drug Discovery Foundation

Leen Kawas, President & CEO, M3 Biotechnology, Inc.

Murali Gopalakrishnan, Senior Director & Head, Search & Evaluation Neuroscience, AbbVie, Inc.

**11:05**

### Rare & Orphan Diseases Panel

Chaired by:

Mark Day, Head, CNS Virtual Discovery, Purdue Pharma L.P.

Panelists:

Allison Moore, Founder & CEO, Hereditary Neuropathy Foundation

Chaim Lebovits, CEO, BrainStorm Cell Therapeutics, Inc.

Jak Knowles, Managing Director and VP Medical and Scientific Affairs, CureDuchenne Ventures

Luca Benatti, CEO, Erydel SpA

Marc Martinell, CEO, Minoryx Therapeutics S.L.

**11:35**

### Neuropsychiatry & Pain Management Panel

Chaired by:

Maxim Jacobs, Senior Healthcare Analyst, Edison Investment Research

Panelists:

Bob Linke, President & CEO, Embera NeuroTherapeutics, Inc.

Gerhard Koenig, President & CEO, Quartet Medicine

Jonathan Javitt, CEO, NeuroRx, Inc.

Wayne Drevets, VP, Disease Area Leader in Mood Disorders, Neuroscience, Janssen Pharmaceutical Companies of Johnson & Johnson, Inc.

**12:15** Networking Lunch

PR Companies Track A  
Moderated by: John Nolan, WBB Securities, LLC

**10:25** ASDERA

**10:45** Cantabio Pharmaceuticals, Inc.  
[OTCMKTS:LIOCD]

**11:05** Purdue Pharma L.P.

**11:25** Probiodrug AG  
[AMS:PBD]

**11:45** ProMIS™ Neurosciences, Inc.  
[TSE:PMN]

**12:05** M3 Biotechnology, Inc.

**12:15** Networking Lunch

**13:15** Keynote Speech: "A Regenerative Approach to Neurodegenerative Diseases" by Dr. Daniel Alkon, President and CSO, Neurotrope Bioscience, Inc.

**13:35** **Advances in Parkinson's Disease & Other Movement Disorders Panel**

Chaired by:

Ginger Johnson, CEO, Defined Health, a Cello Health business

Panelists:

Alexander Breidenbach, Director, Global BD Neuroscience, F. Hoffmann-La Roche Ltd.

David Donabedian, Co-Founder and CEO, Axial Biotherapeutics

Jon Kaiser, CEO, K-PAX Pharmaceuticals, Inc.

Kees Been, Founder, President and CEO, Lysosomal Therapeutics, Inc.

Kenneth Rhodes, CSO, Yumanity Therapeutics

**PR Companies Track C**

Moderated by: Robert Wotczak, Wotczak Group

**14:20** Brainstorm Cell Therapeutics, Inc.  
[NASDAQ:BCLI]

**14:40** Oryzon Genomics SA  
[BME:ORY]

**15:00** Neurotrope Bioscience, Inc.  
[OTCQB:NTRP]

**15:20** KemPharm, Inc.  
[NASDAQ:KMPH]

**15:40** SunRegen Healthcare AG

**16:20** Coffee Break

**16:35** **Investor Roundtable**

Chaired by:

Steve Dickman, CEO, CBT Advisors

Panelists:

Daniel O'Connell, Investment Manager, Arix Bioscience

Jason Park, Principal, Flagship Ventures

Kristen Kosofsky, Sr. Managing Director, Hercules Technology Growth Capital, Inc.

Vincent Miles, Partner, Abingworth LLP

**17:20** Networking Reception

**18:30** End of the 2<sup>nd</sup> NBPI Forum

**PR Companies Track B**

Moderated by: Emad Samad, WBB Securities, LLC

**13:35** Nexeon Medsystems, Inc.

**13:45** SalubRx Therapeutics, Inc.

**13:55** Pharmasum Therapeutics AS

**14:05** vasopharm GmbH

**14:15** T3D Therapeutics, Inc.

**14:25** EryDel SpA

**14:35** Minoryx Therapeutics S.L.

**14:45** K-PAX Pharmaceuticals, Inc.

**PR Companies Track D**

Moderated by: Leonard Sachs, Sachs Associates

**15:10** Exscientia Ltd.

**15:20** NeuroRx, Inc.

**15:40** Embera NeuroTherapeutics, Inc.

**16:00** Quartet Medicine

Sponsored by:



Supported by:

